$BLLN

Sakakibara Shan Riku sold $880K of BLLN

Sakakibara Shan Riku (Chief Product Officer) sold 8,000 shares of BillionToOne, Inc. (BLLN) at $110.00 ($0.88M total) across 2 trades on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sakakibara Shan Riku
Published Jun 26, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling activity (8,000 shares at $110/share) but does not introduce new operating or financial information.

02

Market read

Traders may treat this as a minor sentiment input rather than a fundamental catalyst due to the 10b5-1 structure.

03

What to watch

The filing doesn’t disclose new fundamentals (no guidance, trial, or deal). The only actionable element is monitoring for additional insider transactions or corroborating catalysts.

Relevance 4/10Novelty 4/10Timing: filed after-hours on 2026-06-26; reflects trades dated 2026-06-24

Background

The article is an SEC Form 4 insider transaction disclosure for BillionToOne, Inc. (BLLN).

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

SEC Form 4 shows BLLN CPO Sakakibara Shan Riku sold 8,000 shares at $110/share under a 10b5-1 plan, totaling $880k.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived unless paired with other disclosures.

Evidence & confidence

The filing is a pre-arranged 10b5-1 open-market sale, which reduces interpretive weight versus discretionary selling.

Market effects

No sector-level read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 plan, the sale may be purely mechanical and not a bearish signal; traders may ignore it absent follow-on news.

Key entities

  • BillionToOne, Inc.

    Subject of the Form 4 insider sale by its Chief Product Officer.

  • Sakakibara Shan Riku

    Chief Product Officer who sold 8,000 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BLLNLow

BillionToOne's Northstar Response Shows High Concordance In Advanced Cancer Study

BillionToOne (BLLN) published a study showing its Northstar Response liquid biopsy assay had high concordance with a commercial ctDNA assay in advanced cancer patients. The study of 61 patients found 94% agreement in tumor burden change direction, with Northstar Response aligning with clinical ground truth in discordant cases. The assay detects disease progression even when tumors evolve post-biopsy. BLLN shares closed at $22.71, down 0.79%.

$BLLNMedAI 8/10

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

BillionToOne (BLLN) announced a peer-reviewed study showing its Northstar Response® liquid biopsy assay performed on par or better than a tumor-informed assay in tracking cancer treatment. The study, published in The Journal of Liquid Biopsy, evaluated 169 samples from 61 patients, finding close alignment in results (R² = 0.97) and agreement in 94% of cases. Northstar Response detected disease progression in cases where the tumor-informed assay did not, highlighting its tumor-agnostic benefits.

$BLLNMedAI 8/10

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.

$BLLNMed

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance MENLO PARK, CA, August 5, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to al

$BLLNMedAI 8/10

Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

BillionToOne (NASDAQ: BLLN) saw multiple analyst rating and target changes. Weiss Ratings upgraded BLLN to “sell (d+)” (from “sell (d)”) on 5/15 and reaffirmed “sell (d)” on 5/1. Guggenheim raised its target to $120 (from $100) and kept a “buy” on 5/13. JPMorgan lifted its target to $125 and maintained “overweight” on 5/7. BTIG cut its target to $130 (from $140) while keeping “buy” on 5/7.